BELLEVUE, Wash., April 15, 2021 /PRNewswire/ -- Viome,
a mission-driven systems biology company aiming to help individuals
improve their health, today announced the appointment of Dr.
Emmanuel Hanon as Global Head
of Research and Development (R&D). Dr. Hanon is a healthcare
veteran hailing from GlaxoSmithKline plc (LSE/NYSE: GSK), where he
spent more than 20 years in R&D roles, most recently as senior
vice president, head of vaccine research and development and a core
member of the pharmaceutical company's Vaccine Executive Team.
As global head of R&D for the vaccine group at GSK, Dr.
Hanon oversaw more than 3,500 employees across 50 countries
dedicated to delivering discovery, development and management
activities for the company's vaccine efforts. Additionally, Dr.
Hanon was responsible for the shared science and technology
platforms supporting the entire vaccine business, managing
technical development, clinical immunology, and preclinical stages
of vaccine developments. Since joining GSK in 2001, Dr.
Emmanuel Hanon has contributed to
the development of many vaccines targeting human papilloma virus,
malaria, tuberculosis, seasonal and pandemic Influenza, Shingles,
Meningitis, and RSV.
"I am very grateful for my time with GlaxoSmithKline, which
allowed me to transform my scientific curiosity into preventative
interventions that have the potential to help millions of people,"
said Dr. Emmanuel Hanon. "Since
establishing partnerships between GSK and Viome a few years ago, I
have been blown away by the company's technology and truly believe
that its focus on precision medicine is the future of
healthcare."
In his new role at Viome, Hanon will work closely with CEO and
founder, Naveen Jain, to lead
Viome's therapeutics efforts. Emmanuel
Hanon will be leading the science team to identify
host/microbial interactions from Viome's unique database of gene
expression and to turn this knowledge into vaccines and drugs to
prevent and intercept chronic diseases. He officially begins his
new role as Global Head of R&D on July
1 but will immediately join the Science Advisory Board of
Viome.
"The healthcare industry is at an inflection point as humanity
struggles with the epidemic of chronic diseases," said Naveen Jain, CEO and Founder of Viome. "We need
to move away from managing the symptoms of the chronic diseases and
focus on understanding the root causes of chronic diseases,
cancers, and aging. The only way to do that is to take advantage of
massive datasets that are indicative of progression of diseases and
use powerful Artificial Intelligence to identify the mechanisms of
action. I am excited for Dr. Hanon to bring his deep expertise in
therapeutics development and turn these beliefs into a reality that
will positively transform our healthcare system and humanity."
About Viome
Viome was founded in 2016 with a mission
to make illness optional by predicting and preventing chronic
diseases through a deeper understanding of an individual's biology
at a molecular level. Viome is the industry's only
direct-to-consumer healthcare company that analyzes microbial and
human gene expressions (mRNA), with technology exclusively licensed
from Los Alamos National Lab, in order to provide individuals with
health insights and the nutrition they need.
Today, Viome has become a global healthcare company, developing
precision nutrition, precision drugs, and precision vaccines to
help people live a disease free life. Viome has developed a state
of the art artificial intelligence platform that analyzes the data
from the world's largest and richest gene expression database in
order to identify the root causes of chronic diseases and the
mechanisms of action to be able to prevent and reverse these
diseases.
Contact: viome@factorypr.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/gsk-global-head-of-vaccine-research-and-development-joins-viome-to-tackle-chronic-diseases-301269769.html
SOURCE Viome